The authors found mutations in four genes in the NRF2‐ARE pathway in 10% of pRCCs tested, and they also found that overexpression of the reductase NQO1 correlated with worse survival and higher tumor grade and stage. This evidence concerns the gene NFE2L2 and neoplasm.